- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mangoceuticals Inc (MGRX)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.3760
0.4080
52 wk Range
0.1620
2.7500
MGRX Income Statement
Featured here, the Income Statement (earnings report) for Mangoceuticals Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
| Period Ending: | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | 2025 31/12 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | - | 0.01 | 0.73 | 0.62 | 0.46 | |||||||||||||||||||||||||||||
Total Revenues Growth | - | - | +8,083.16% | -15.81% | -25.96% | |||||||||||||||||||||||||||||
Cost Of Revenues | - | 0 | 0.3 | 0.24 | 0.21 | |||||||||||||||||||||||||||||
Gross Profit | - | 0 | 0.43 | 0.38 | 0.25 | |||||||||||||||||||||||||||||
Gross Profit Growth | - | - | +8,796.93% | -11.94% | -34.1% | |||||||||||||||||||||||||||||
Gross Profit Margin % | - | 54.26% | 58.99% | 61.7% | 54.91% | |||||||||||||||||||||||||||||
Other Operating Expenses, Total | 0.07 | 2 | 8.55 | 8.62 | 17.84 | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
Operating Income | -0.07 | -1.99 | -8.12 | -8.24 | -17.59 | |||||||||||||||||||||||||||||
Operating Income Growth | - | -2,741.87% | -307.64% | -1.49% | -113.52% | |||||||||||||||||||||||||||||
EBIT Margin % | - | -22,279.7% | -1,109.84% | -1,337.9% | -3,858.11% | |||||||||||||||||||||||||||||
Net Interest Expenses | -0 | -0.01 | 0.01 | -0.01 | -0.1 | |||||||||||||||||||||||||||||
Net Interest Expenses Growth | - | -794.06% | +200% | -311.65% | -655.57% | |||||||||||||||||||||||||||||
Interest Expense, Total | -0 | -0.01 | - | -0.01 | -0.1 | |||||||||||||||||||||||||||||
Interest And Investment Income | - | - | 0.01 | - | - | |||||||||||||||||||||||||||||
Other Non Operating Expenses, Total | - | - | -1.1 | -0.45 | -1.56 | |||||||||||||||||||||||||||||
EBT, Excl. Unusual Items | -0.07 | -2 | -9.21 | -8.71 | -19.26 | |||||||||||||||||||||||||||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||||||||||||||||||||||||||
Other Unusual Items, Total | - | - | - | - | -1.38 | |||||||||||||||||||||||||||||
EBT, Incl. Unusual Items | -0.07 | -2 | -9.21 | -8.71 | -20.64 | |||||||||||||||||||||||||||||
EBT, Incl. Unusual Items Growth | - | -2,721.95% | -361.07% | +5.48% | -137.08% | |||||||||||||||||||||||||||||
EBT, Incl. Unusual Items Margin | - | -22,352.11% | -1,259.4% | -1,413.8% | -4,526.86% | |||||||||||||||||||||||||||||
Income Tax Expense | - | - | - | - | - | |||||||||||||||||||||||||||||
Net Income to Company | -0.07 | -2 | -9.21 | -8.71 | -20.64 | |||||||||||||||||||||||||||||
Minority Interest | - | - | - | 0 | 0 | |||||||||||||||||||||||||||||
Net Income | -0.07 | -2 | -9.21 | -8.71 | -20.64 | |||||||||||||||||||||||||||||
Net Income Growth | - | -2,721.95% | -361.07% | +5.5% | -137.11% | |||||||||||||||||||||||||||||
Net Income Margin % | - | -22,352.11% | -1,259.4% | -1,413.63% | -4,526.76% | |||||||||||||||||||||||||||||
Preferred Dividend and Other Adjustments | - | - | - | 0.8 | 1.18 | |||||||||||||||||||||||||||||
Net Income to Common Excl. Extra Items | -0.07 | -2 | -9.21 | -9.51 | -21.82 | |||||||||||||||||||||||||||||
Basic EPS - Continuing Operations | - | -2.78 | -8.58 | -4.8 | -2.17 | |||||||||||||||||||||||||||||
Basic EPS - Continuing Operations Growth | - | - | -208.98% | +43.98% | +54.91% | |||||||||||||||||||||||||||||
Diluted EPS - Continuing Operations | - | -2.78 | -8.58 | -4.8 | -2.17 | |||||||||||||||||||||||||||||
Diluted EPS - Continuing Operations Growth | - | - | -208.98% | +43.98% | +54.91% | |||||||||||||||||||||||||||||
Basic Weighted Average Shares Outstanding | 0.53 | 0.72 | 1.07 | 1.98 | 10.07 | |||||||||||||||||||||||||||||
Diluted Weighted Average Shares Outstanding | 0.53 | 0.72 | 1.07 | 1.98 | 10.07 | |||||||||||||||||||||||||||||
Dividend Per Share | - | - | - | - | - | |||||||||||||||||||||||||||||
Dividend Per Share Growth | - | - | - | - | - | |||||||||||||||||||||||||||||
EBITDA | - | -1.99 | -8.09 | -7.51 | -15.87 | |||||||||||||||||||||||||||||
EBITDA Growth | - | - | -307.18% | +7.23% | -111.36% | |||||||||||||||||||||||||||||
EBITDA Margin % | - | -22,236.48% | -1,106.44% | -1,219.13% | -3,480.01% | |||||||||||||||||||||||||||||
EBIT | -0.07 | -1.99 | -8.12 | -8.24 | -17.59 | |||||||||||||||||||||||||||||
* In Millions of USD (except for per share items)
FAQ
What was Mangoceuticals’s revenue at year end?
At the end of the last reported fiscal year, Mangoceuticals (MGRX) recorded total revenue of 0.4560 million USD.
How much revenue did Mangoceuticals report in the most recent quarter?
In its most recent quarterly earnings report, Mangoceuticals posted revenue of 0.0688 million USD.
What was Mangoceuticals’s net income for the year?
For the full year, Mangoceuticals reported net income of -20.6430 million USD.
How much net income did Mangoceuticals post in the last quarter?
In the most recent quarter, Mangoceuticals (MGRX) posted net income of -1.3127 million USD.
What was Mangoceuticals’s gross profit for the year?
Gross profit for the year was reported at 0.2504 million USD.
How much gross profit did Mangoceuticals generate last quarter?
Mangoceuticals recorded gross profit of 0.0442 million USD in its latest quarterly report.
What was Mangoceuticals’s annual operating income?
For the full year, Mangoceuticals (MGRX) reported operating income of -17.5938 million USD.
What was Mangoceuticals’s operating income last quarter?
Quarterly operating income was -1.0330 million USD.
What was Mangoceuticals’s quarterly EBITDA?
In the latest quarter, EBITDA was reported at -0.7382 million USD.
What was the quarter-over-quarter change in EBITDA for Mangoceuticals?
EBITDA changed by 73.8434% million USD compared to the last quarter.
What is Mangoceuticals’s most recent gross profit margin?
The latest reported gross profit margin for Mangoceuticals (MGRX) is 64.3061% million USD.
What is Mangoceuticals’s most recent net income margin?
Net income margin based on recent financials is -1,909.1190% million USD.
What is Mangoceuticals’s most recent EBIT margin?
Mangoceuticals reported an EBIT margin of -1,502.4506% million USD based on current figures.
How did Mangoceuticals’s revenue change compared to the previous quarter?
Revenue changed by 1.3159% million USD compared to the prior quarter.
What was the quarter-over-quarter change in gross profit for Mangoceuticals?
In the latest quarter, gross profit changed by 52.4603% million USD from the previous quarter.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.